Ionis Pharmaceuticals (MIL:1IONS) Piotroski F-Score: 3 (As of Aug. 02, 2026) — 40% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1IONS Ionis Pharmaceuticals Inc MIL:1IONS
48 GF Score
Price €48.44
GF Value €44.73
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Piotroski F-Score?

Ionis Pharmaceuticals MIL:1IONS 48 Piotroski F-Score is 3 as of Aug. 02, 2026, which is 40% below its 10-year median of 5.00. GuruFocus rates MIL:1IONS with a GF Score™ of 48/100 and a GF Value™ of €44.73 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,331 Biotechnology companies, Ionis Pharmaceuticals ranks better than 54.62% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ionis Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Ionis Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

MIL:1IONS' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Ionis Pharmaceuticals was 7. The lowest was 1. And the median was 5.

Ionis Pharmaceuticals  (MIL:1IONS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Ionis Pharmaceuticals Piotroski F-Score Related Terms


Ionis Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Piotroski F-Score Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 0.00 4.00 2.00 3.00

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 3.00 2.00 3.00

MIL:1IONS vs KYMR, PRAX, HALO: Piotroski F-Score Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Piotroski F-Score falls into.


MIL:1IONS
48GF Score
Ionis Pharmaceuticals Inc MIL:1IONS
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was -109.572 + -195.902 + -80.037 + -99.513 = €-485.0 Mil.
Cash Flow from Operations was -111.984 + -117.603 + -685.788 + 490.881 = €-424.5 Mil.
Revenue was 133.525 + 173.644 + 212.869 + 232.58 = €752.6 Mil.
Gross Profit was 131.533 + 166.849 + 210.274 + 230.202 = €738.9 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(2588.11 + 2584.194 + 3009.356 + 2984.223 + 2599.227) / 5 = €2753.022 Mil.
Total Assets at the begining of this year (Jun25) was €2,588.1 Mil.
Long-Term Debt & Capital Lease Obligation was €1,400.5 Mil.
Total Current Assets was €2,162.4 Mil.
Total Current Liabilities was €274.0 Mil.
Net Income was -126.572 + -99.653 + -135.918 + 107.119 = €-255.0 Mil.

Revenue was 120.566 + 216.38 + 121.741 + 391.926 = €850.6 Mil.
Gross Profit was 119.601 + 212.722 + 120.354 + 388.328 = €841.0 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(2500.058 + 2776.07 + 2868.51 + 2601.977 + 2588.11) / 5 = €2666.945 Mil.
Total Assets at the begining of last year (Jun24) was €2,500.1 Mil.
Long-Term Debt & Capital Lease Obligation was €684.8 Mil.
Total Current Assets was €2,234.4 Mil.
Total Current Liabilities was €777.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ionis Pharmaceuticals's current Net Income (TTM) was -485.0. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Ionis Pharmaceuticals's current Cash Flow from Operations (TTM) was -424.5. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=-485.024/2588.11
=-0.18740471

ROA (Last Year)=Net Income/Total Assets (Jun24)
=-255.024/2500.058
=-0.10200723

Ionis Pharmaceuticals's return on assets of this year was -0.18740471. Ionis Pharmaceuticals's return on assets of last year was -0.10200723. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Ionis Pharmaceuticals's current Net Income (TTM) was -485.0. Ionis Pharmaceuticals's current Cash Flow from Operations (TTM) was -424.5. ==> -424.5 > -485.0 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=1400.537/2753.022
=0.50872714

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=684.82/2666.945
=0.2567807

Ionis Pharmaceuticals's gearing of this year was 0.50872714. Ionis Pharmaceuticals's gearing of last year was 0.2567807. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=2162.426/273.974
=7.89281465

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=2234.389/777.904
=2.87231972

Ionis Pharmaceuticals's current ratio of this year was 7.89281465. Ionis Pharmaceuticals's current ratio of last year was 2.87231972. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Ionis Pharmaceuticals's number of shares in issue this year was 165.419. Ionis Pharmaceuticals's number of shares in issue last year was 182.331. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=738.858/752.618
=0.98171715

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=841.005/850.613
=0.98870462

Ionis Pharmaceuticals's gross margin of this year was 0.98171715. Ionis Pharmaceuticals's gross margin of last year was 0.98870462. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=752.618/2588.11
=0.2907983

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=850.613/2500.058
=0.34023731

Ionis Pharmaceuticals's asset turnover of this year was 0.2907983. Ionis Pharmaceuticals's asset turnover of last year was 0.34023731. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Ionis Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Ionis Pharmaceuticals (MIL:1IONS) has a Piotroski F-Score of 3 as of Aug. 02, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ionis Pharmaceuticals and its competitors. This is 40% below median its historical median of 5.00. Over the past decade, Ionis Pharmaceuticals' Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Ionis Pharmaceuticals ranks #604 out of 1331 companies in the Biotechnology industry, placing it in the top 45.4%.
Is Ionis Pharmaceuticals' Piotroski F-Score too high?
Ionis Pharmaceuticals' current Piotroski F-Score of 3 is 40% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Ionis Pharmaceuticals' value of 3 is 0% at this industry median. Based on the distribution chart, Ionis Pharmaceuticals ranks #604 out of 1331 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ionis Pharmaceuticals has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Piotroski F-Score compare to KYMR and PRAX?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #604 out of 1331 companies for Piotroski F-Score. This puts Ionis Pharmaceuticals in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Ionis Pharmaceuticals' value of 3 is 0% at this benchmark. Historically, Ionis Pharmaceuticals' own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Ionis Pharmaceuticals has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,331 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ionis Pharmaceuticals's current Piotroski F-Score of 3 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current Piotroski F-Score is 3, which is 40% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (MIL:1IONS) is currently considered Modestly Overvalued. The stock's GF Value™ is €44.73, compared to a current price of €48.44 — trading 8.3% above its estimated fair value. The current Piotroski F-Score is 3, which is 40% below median its 10-year median of 5.00 and 0% at the Biotechnology industry median of 3.00. Ionis Pharmaceuticals' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Ionis Pharmaceuticals (MIL:1IONS), the current Piotroski F-Score is 3 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MIL:1IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €48.44 is trading 8.3% above its estimated GF Value™ of €44.73. GuruFocus considers Ionis Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for MIL:1IONS:

  • Piotroski F-Score: 3 (40% below median its 10-year median of 5.00)
  • GF Value™: €44.73 vs. price of €48.44 (8.3% above fair value)
  • GF Score™: 48/100 with 5 warning signs
  • Industry Position: 0% at the Biotechnology median (#604 of 1331)

No single metric tells the full story. See the MIL:1IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA0JDI:UKISI:Germany
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
48GF Score

Get the complete analysis for MIL:1IONS

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.44
Price
€44.73
GF Value